These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24702722)

  • 21. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M; Lippi G
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 23. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in the treatment of acquired factor VIII inhibitors.
    Wiestner A; Cho HJ; Asch AS; Michelis MA; Zeller JA; Peerschke EI; Weksler BB; Schechter GP
    Blood; 2002 Nov; 100(9):3426-8. PubMed ID: 12384448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
    Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
    J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
    Carcao M; St Louis J; Poon MC; Grunebaum E; Lacroix S; Stain AM; Blanchette VS; Rivard GE;
    Haemophilia; 2006 Jan; 12(1):7-18. PubMed ID: 16409170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort.
    Collins PW; Mathias M; Hanley J; Keeling D; Keenan R; Laffan M; Perry D; Liesner R;
    J Thromb Haemost; 2009 May; 7(5):787-94. PubMed ID: 19320828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
    Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
    Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis.
    Franchini M; Mengoli C; Lippi G; Targher G; Montagnana M; Salvagno GL; Zaffanello M; Cruciani M
    Haemophilia; 2008 Sep; 14(5):903-12. PubMed ID: 18671801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress toward inducing immunologic tolerance to factor VIII.
    Scott DW; Pratt KP; Miao CH
    Blood; 2013 May; 121(22):4449-56. PubMed ID: 23502223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired hemophilia: a clinical experience.
    Mirza MA; Khimani F; Rogers J
    W V Med J; 2010; 106(7):32-5. PubMed ID: 21932489
    [No Abstract]   [Full Text] [Related]  

  • 38. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
    Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
    J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors.
    Livnat T; Budnik I; Levy-Mendelovich S; Avishai E; Misgav M; Barg AA; Lubetsky A; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2017 Jul; 66():1-5. PubMed ID: 28689155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.